AGF Investments LLC’s CRISPR Therapeutics CRSP Stock Holding History

AGF Investments LLC’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.64M	Buy	+25,111	New	+$1.82M	0.15%	51

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AGF Investments LLC's CRSP Position: Q3 2022 in Review

AGF Investments LLC opened a new position in CRISPR Therapeutics (CRSP) in Q3 2022: 25,111 shares worth $1.64M. The stake represents 0.15% of the portfolio and ranks #51 among its holdings.

436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

AGF Investments LLC held 25,111 shares of CRISPR Therapeutics worth $1.64M as of Q3 2022.
CRISPR Therapeutics was a new AGF Investments LLC position in Q3 2022.
CRISPR Therapeutics made up 0.15% of AGF Investments LLC's portfolio in Q3 2022, its #51 holding.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on AGF Investments LLC's 13F filing for Q3 2022, filed 10 Nov 2022.